More PsA pts on DEUC vs PBO achieved each of the MDA components at 16 weeks. Abs 2136 #ACR22 @RheumNow https://t.co/OrrDWfvGty https://t.co/CdCQzmgOOO
Links:
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 T…
http://ow.ly/FAjC50LAlz5
14-11-2022